News & Media

Newsroom

SK life science Announces FDA Clearance of IND Application for its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors

1.13.2022

SK life science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome

1.6.2022

SK Biopharmaceuticals Enters into Licensing Agreement with Endo for Cenobamate in Canada

12.23.2021

SK life science Presents Long-Term Data of XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset Seizures at the American Epilepsy Society 2021 Annual Meeting

12.3.2021

SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2021 Annual Meeting

11.29.2021

Welcome to the news and information center for SK Life Science, Inc.

To learn more about SK Life Science, please download our corporate fact sheet

For more information about epilepsy, please download this infographic

For more information about Lennox-Gastaut syndrome, please download this fact sheet

X Community Guidelines

LinkedIn Community Guidelines

Bluesky Community Guidelines

SK Life Science at a Glance

Headquarters Location: Paramus, NJ

R&D Begins: 1993

Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group

Number of Employees: 200+ Employees

Disease Category Focus: CNS Disorders and Oncology

Pipeline: 8 compounds under clinical development

Top